{
    "hands_on_practices": [
        {
            "introduction": "A central challenge in managing *Clostridioides difficile* infection (CDI) is distinguishing true, toxin-mediated disease from asymptomatic colonization, especially when diagnostic tests yield conflicting results. This practice guides you through a quantitative approach to this dilemma, using Bayesian inference and a treatment-threshold analysis to make a rational clinical decision based on a common but complex scenario . Mastering this framework is essential for avoiding both the undertreatment of genuine infection and the overtreatment of colonization.",
            "id": "4634778",
            "problem": "A hospitalized adult receiving broad-spectrum antibiotics develops loose stools, and the laboratory returns a discordant diagnostic result for Clostridioides difficile infection (CDI). You must decide whether to withhold anti–Clostridioides difficile therapy by reasoning from first principles about colonization versus infection, test performance, and the downstream effects of antimicrobial exposure on the gut microbiome and recurrence.\n\nA 67-year-old man on hospital day 4 has had 2 unformed stools in the last 24 hours after receiving ceftriaxone for community-acquired pneumonia and polyethylene glycol for constipation two days earlier. His temperature is $36.9\\,^{\\circ}\\mathrm{C}$, heart rate $84\\,\\mathrm{min}^{-1}$, blood pressure $132/74\\,\\mathrm{mmHg}$, white blood cell count $9{,}800/\\mu\\mathrm{L}$ (baseline $8{,}400/\\mu\\mathrm{L}$), and serum creatinine $0.9\\,\\mathrm{mg/dL}$ (baseline $0.9\\,\\mathrm{mg/dL}$). There is no abdominal tenderness, ileus, or distention. Stool was sent despite not meeting the institutional testing criteria of $\\geq 3$ unformed stools in 24 hours. The stool is positive by Nucleic Acid Amplification Test (NAAT) targeting $tcdB$ and negative by toxin enzyme immunoassay (EIA).\n\nUse the following well-tested facts as your starting base:\n- CDI is defined as compatible clinical symptoms plus evidence of toxin-mediated colitis due to toxigenic Clostridioides difficile; asymptomatic colonization with toxigenic strains is common in hospitalized patients and does not require treatment.\n- NAAT detects the presence of toxigenic genes and has high analytical sensitivity but can be positive in colonization. Toxin EIA detects free toxin and correlates more closely with clinically significant toxin-mediated disease but has imperfect sensitivity.\n- Broad-spectrum oral anti–Clostridioides difficile antibiotics disrupt the gut microbiome to varying degrees; oral vancomycin markedly perturbs the microbiome and increases risk of future Clostridioides difficile acquisition/recurrence relative to no treatment, whereas fidaxomicin is more microbiota-sparing but still exerts selective pressure.\n- In diagnostic decision-making, the post-test probability can be estimated via Bayes’ theorem from a clinically estimated pretest probability and test characteristics, and a rational treatment threshold can be set by comparing expected benefit and harm.\n\nFor this patient, your institution’s infectious diseases service has published the following parameters derived from local data for clinically significant toxin-mediated CDI among patients with low pretest probability features (fewer than $3$ unformed stools in $24$ hours and recent laxative use), which you may assume are applicable here:\n- Estimated pretest probability of toxin-mediated CDI: $P(D)=0.10$.\n- NAAT sensitivity $P(\\text{NAAT}+\\mid D)=0.95$ and specificity $P(\\text{NAAT}-\\mid \\neg D)=0.90$ for toxin-mediated CDI.\n- Toxin EIA sensitivity $P(\\text{Toxin}+\\mid D)=0.60$ and specificity $P(\\text{Toxin}-\\mid \\neg D)=0.95$ for toxin-mediated CDI.\n- For the purpose of this calculation, assume conditional independence of NAAT and toxin EIA given the true disease state.\n- If toxin-mediated CDI is present and immediate therapy is initiated in non-severe cases, the absolute risk reduction in serious clinical deterioration (composite of progression to severe colitis, need for intensive care, colectomy, or death) is approximately $B=0.05$ relative to careful observation with supportive care over the next $48$ hours.\n- If toxin-mediated CDI is absent and oral vancomycin is given unnecessarily, the absolute risk increase for subsequent clinically significant CDI within $60$ days due to microbiome disruption is approximately $H=0.05$ compared with withholding therapy. Assume oral vancomycin is the only formulary-restricted first-line agent readily available at this time.\n\nBased on first principles and these data, which of the following is the most appropriate next step?\n\nA. Withhold anti–Clostridioides difficile therapy now; stop laxatives and de-escalate non–Clostridioides difficile antibiotics if possible, maintain enteric isolation, and reassess in $24$–$48$ hours; initiate therapy only if symptoms persist or worsen or if severe features develop.\n\nB. Initiate oral vancomycin now because NAAT positivity indicates the presence of a toxigenic strain and recent systemic antibiotics increase risk.\n\nC. Initiate fidaxomicin now to minimize microbiome disruption despite a negative toxin EIA, because early therapy reduces complications even in mild cases.\n\nD. Administer bezlotoxumab alone to prevent recurrence while withholding antibiotics, given the negative toxin EIA.\n\nE. Repeat NAAT immediately on a new stool specimen; if still positive, treat for CDI.",
            "solution": "The problem asks for the most appropriate clinical decision for a hospitalized patient with mild diarrhea and a discordant *Clostridioides difficile* infection (CDI) test result. The decision must be derived from first principles, including Bayesian reasoning and a treatment threshold analysis based on provided data.\n\n### Step 1: Validation of the Problem Statement\nThe problem statement provides a detailed clinical scenario, explicit definitions, and quantitative parameters for a decision analysis.\n\n**Givens:**\n-   **Clinical Scenario**: A 67-year-old male on day 4 of hospitalization receiving ceftriaxone. He has had 2 unformed stools in the past 24 hours after also receiving polyethylene glycol. He is afebrile ($36.9\\,^{\\circ}\\mathrm{C}$) and hemodynamically stable. His white blood cell count and serum creatinine are essentially unchanged from baseline. His abdomen is non-tender.\n-   **Diagnostic Results**: Stool Nucleic Acid Amplification Test (NAAT) for $tcdB$ is positive. Stool toxin enzyme immunoassay (EIA) is negative.\n-   **Context**: The patient did not meet institutional testing criteria of $\\ge 3$ unformed stools in $24$ hours.\n-   **Definitions and Principles**:\n    1.  CDI requires both symptoms and evidence of toxin-mediated disease. Asymptomatic colonization does not require treatment.\n    2.  NAAT is sensitive for toxigenic genes but can be positive in colonization. Toxin EIA is more specific for active disease but has lower sensitivity.\n    3.  Anti-CDI antibiotics disrupt the microbiome and increase future risk.\n    4.  Decision-making can be guided by Bayes' theorem and a treatment threshold comparing benefit and harm.\n-   **Quantitative Parameters for this patient's low pretest probability group**:\n    -   Pretest probability of toxin-mediated CDI: $P(D) = 0.10$.\n    -   NAAT characteristics: Sensitivity $P(\\text{NAAT}+\\mid D)=0.95$, Specificity $P(\\text{NAAT}-\\mid \\neg D)=0.90$.\n    -   Toxin EIA characteristics: Sensitivity $P(\\text{Toxin}+\\mid D)=0.60$, Specificity $P(\\text{Toxin}-\\mid \\neg D)=0.95$.\n    -   Conditional independence of tests is assumed.\n    -   Benefit of immediate treatment if CDI is present: $B = 0.05$ (absolute risk reduction of progression).\n    -   Harm of unnecessary vancomycin if CDI is absent: $H = 0.05$ (absolute risk increase of future CDI).\n    -   Available agent is oral vancomycin.\n\n**Validation Verdict:**\nThe problem is scientifically grounded, well-posed, and objective. It presents a realistic and common clinical dilemma. All necessary quantitative and qualitative information is provided to perform a rigorous analysis using the specified first principles. The parameters are internally consistent and plausible. The problem is valid.\n\n### Step 2: Derivation of the Solution\n\nThe core task is to calculate the post-test probability of toxin-mediated CDI given the patient's test results and compare this to a rationally derived treatment threshold.\n\n**A. Calculation of Post-Test Probability of Disease**\nWe need to find the probability of disease ($D$) given the evidence ($E$), which consists of a positive NAAT ($\\text{NAAT}+$) and a negative Toxin EIA ($\\text{Toxin}-$). The post-test probability is $P(D \\mid \\text{NAAT}+, \\text{Toxin}-)$. Using Bayes' theorem:\n$$ P(D \\mid E) = \\frac{P(E \\mid D) P(D)}{P(E \\mid D) P(D) + P(E \\mid \\neg D) P(\\neg D)} $$\nDue to conditional independence of the tests:\n$P(E \\mid D) = P(\\text{NAAT}+ \\mid D) \\times P(\\text{Toxin}- \\mid D)$\n$P(E \\mid \\neg D) = P(\\text{NAAT}+ \\mid \\neg D) \\times P(\\text{Toxin}- \\mid \\neg D)$\n\nFirst, we compile the necessary probabilities from the givens:\n-   $P(D) = 0.10$\n-   $P(\\neg D) = 1 - P(D) = 1 - 0.10 = 0.90$\n-   $P(\\text{NAAT}+ \\mid D) = 0.95$\n-   $P(\\text{Toxin}- \\mid D) = 1 - P(\\text{Toxin}+ \\mid D) = 1 - 0.60 = 0.40$\n-   $P(\\text{NAAT}+ \\mid \\neg D) = 1 - P(\\text{NAAT}- \\mid \\neg D) = 1 - 0.90 = 0.10$\n-   $P(\\text{Toxin}- \\mid \\neg D) = 0.95$\n\nNow, we calculate the joint likelihoods:\n-   Likelihood of the evidence if disease is present: $P(E \\mid D) = 0.95 \\times 0.40 = 0.38$\n-   Likelihood of the evidence if disease is absent: $P(E \\mid \\neg D) = 0.10 \\times 0.95 = 0.095$\n\nNext, we substitute these into Bayes' theorem:\n$$ P(D \\mid \\text{NAAT}+, \\text{Toxin}-) = \\frac{(0.38)(0.10)}{(0.38)(0.10) + (0.095)(0.90)} $$\n$$ P(D \\mid \\text{NAAT}+, \\text{Toxin}-) = \\frac{0.038}{0.038 + 0.0855} = \\frac{0.038}{0.1235} \\approx 0.3077 $$\nThe post-test probability that this patient has clinically significant, toxin-mediated CDI is approximately $30.8\\%$.\n\n**B. Calculation of the Treatment Threshold**\nThe decision to treat is rational if the expected benefit of treatment exceeds the expected harm. The treatment threshold probability, $p_T$, is the point of equipoise where the expected benefit of treating equals the expected harm of treating. This occurs when the net expected utility of treatment is zero.\n$$ p_T \\times B = (1 - p_T) \\times H $$\nwhere $B$ is the benefit of treating a true positive and $H$ is the harm of treating a false positive.\nRearranging for $p_T$:\n$$ p_T = \\frac{H}{B + H} $$\nUsing the provided values $B=0.05$ and $H=0.05$:\n$$ p_T = \\frac{0.05}{0.05 + 0.05} = \\frac{0.05}{0.10} = 0.50 $$\nThe treatment threshold is $50\\%$. Treatment should be initiated only if the post-test probability of disease is greater than $50\\%$.\n\n**C. Decision Synthesis**\nThe calculated post-test probability of CDI is $p \\approx 30.8\\%$. The calculated treatment threshold is $p_T = 50\\%$.\nSince $p  p_T$ ($30.8\\%  50\\%$), the quantitative analysis indicates that withholding anti-CDI therapy is the most appropriate action. The expected harm of unnecessary treatment outweighs the expected benefit of treatment at this level of diagnostic certainty.\n\nThis conclusion is strongly supported by the qualitative clinical data: the patient is stable, has mild symptoms that may be attributable to a laxative, and did not meet standard criteria for testing in the first place. The NAAT+/toxin- result is most consistent with asymptomatic colonization, which should not be treated. The appropriate management is therefore to withhold specific CDI therapy, address other contributing factors (laxatives, other antibiotics), implement infection control measures (as the patient is colonized and can be a source of transmission), and monitor for any clinical worsening that would prompt reassessment.\n\n### Step 3: Evaluation of Options\n\n**A. Withhold anti–Clostridioides difficile therapy now; stop laxatives and de-escalate non–Clostridioides difficile antibiotics if possible, maintain enteric isolation, and reassess in $24$–$48$ hours; initiate therapy only if symptoms persist or worsen or if severe features develop.**\n-   **Analysis**: This option aligns perfectly with our derived conclusion. The decision to withhold therapy is justified by the post-test probability ($30.8\\%$) being below the treatment threshold ($50\\%$). The additional management steps (stopping laxatives, antibiotic stewardship, isolation, and watchful waiting) represent a comprehensive and correct clinical plan for managing a patient with probable *C. difficile* colonization and mild, non-specific symptoms.\n-   **Verdict**: **Correct**.\n\n**B. Initiate oral vancomycin now because NAAT positivity indicates the presence of a toxigenic strain and recent systemic antibiotics increase risk.**\n-   **Analysis**: This approach ignores the high probability of colonization, the negative toxin EIA result, the mild clinical picture, and the explicit results of the Bayesian analysis. Treating based on NAAT positivity alone leads to significant overtreatment of colonization, which carries the harm of microbiome disruption and increased future CDI risk, quantified here as $H=0.05$. The formal analysis proves this course of action is not optimal.\n-   **Verdict**: **Incorrect**.\n\n**C. Initiate fidaxomicin now to minimize microbiome disruption despite a negative toxin EIA, because early therapy reduces complications even in mild cases.**\n-   **Analysis**: This option is incorrect for two main reasons. First, the analysis shows that *any* anti-CDI therapy is not currently indicated. Second, the problem statement specifies that oral vancomycin is the only readily available first-line agent, making the suggestion of fidaxomicin contrary to the scenario's constraints. The argument for \"early therapy\" is fallacious when the probability of the disease being present is low and below the calculated treatment threshold.\n-   **Verdict**: **Incorrect**.\n\n**D. Administer bezlotoxumab alone to prevent recurrence while withholding antibiotics, given the negative toxin EIA.**\n-   **Analysis**: This represents a misunderstanding of the indication for bezlotoxumab. Bezlotoxumab is an adjunctive therapy used alongside standard-of-care antibiotics to prevent *recurrence* in high-risk patients. It is not a monotherapy for active CDI, nor is it used for patients who are merely colonized and not receiving CDI treatment. This action is not evidence-based.\n-   **Verdict**: **Incorrect**.\n\n**E. Repeat NAAT immediately on a new stool specimen; if still positive, treat for CDI.**\n-   **Analysis**: This is a clinically unhelpful strategy. The patient is already known to be NAAT-positive, indicating colonization with a toxigenic strain. A repeat NAAT will almost certainly be positive and will not resolve the diagnostic uncertainty of infection versus colonization. The proposed treatment trigger (\"if still positive, treat\") is the same flawed logic as in option B, which our analysis has shown to be inappropriate.\n-   **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "After diagnosing CDI, the next step is selecting the most effective therapy. This exercise focuses on the critical skill of interpreting clinical trial data by calculating absolute and relative risk reductions for two primary CDI treatments . By translating trial outcomes into these fundamental metrics, you can precisely quantify the comparative efficacy of different therapeutic options.",
            "id": "4816233",
            "problem": "A randomized, parallel-group trial in internal medicine evaluated recurrence of Clostridioides difficile infection (CDI) after initial clinical cure, comparing fidaxomicin to vancomycin over a fixed follow-up of 8 weeks. Investigators reported observed recurrence risks (probabilities) of $0.15$ in the fidaxomicin group and $0.25$ in the vancomycin group. Using first-principles definitions grounded in probability and comparative risk analysis, compute the absolute risk reduction and the relative risk reduction for recurrence associated with fidaxomicin relative to vancomycin.\n\nExpress both quantities as decimals (do not use a percentage sign), and round each to $4$ significant figures. Provide the final answer as a row matrix $\\begin{pmatrix}\\text{ARR}  \\text{RRR}\\end{pmatrix}$, where the left entry is the absolute risk reduction and the right entry is the relative risk reduction.",
            "solution": "The problem provides the observed recurrence risks for *Clostridioides difficile* infection (CDI) in two treatment groups from a randomized trial and asks for the computation of two fundamental measures of comparative risk: the absolute risk reduction and the relative risk reduction. The problem is well-posed, scientifically grounded, and contains all necessary information for a unique solution.\n\nLet $P_E$ represent the probability of an adverse event (in this case, CDI recurrence) in the experimental or intervention group. Let $P_C$ represent the probability of the same event in the control or comparator group. Based on the problem statement:\n- The intervention is fidaxomicin.\n- The comparator is vancomycin.\n- The outcome is CDI recurrence.\n- The follow-up period is a fixed 8 weeks.\n\nThe provided probabilities are:\n- Risk in the fidaxomicin group, $P_E = 0.15$.\n- Risk in the vancomycin group, $P_C = 0.25$.\n\nFrom first principles, the absolute risk reduction (ARR) is defined as the arithmetic difference between the event rate in the control group and the event rate in the experimental group. It quantifies the absolute difference in risk attributable to the intervention.\n$$\n\\text{ARR} = P_C - P_E\n$$\nSubstituting the given values:\n$$\n\\text{ARR} = 0.25 - 0.15 = 0.10\n$$\n\nThe relative risk (RR) is the ratio of the risk in the experimental group to the risk in the control group.\n$$\n\\text{RR} = \\frac{P_E}{P_C}\n$$\nThe relative risk reduction (RRR) is the proportional reduction in risk in the experimental group relative to the control group. It is defined as the absolute risk reduction divided by the risk in the control group.\n$$\n\\text{RRR} = \\frac{P_C - P_E}{P_C} = \\frac{\\text{ARR}}{P_C}\n$$\nAlternatively, the RRR can be expressed in terms of the relative risk:\n$$\n\\text{RRR} = 1 - \\text{RR} = 1 - \\frac{P_E}{P_C} = \\frac{P_C - P_E}{P_C}\n$$\nUsing the primary definition and substituting the given values:\n$$\n\\text{RRR} = \\frac{0.25 - 0.15}{0.25} = \\frac{0.10}{0.25}\n$$\nTo simplify this fraction:\n$$\n\\text{RRR} = \\frac{10}{25} = \\frac{2}{5} = 0.4\n$$\nThe problem requires that both results be expressed as decimals rounded to $4$ significant figures.\n\nFor the absolute risk reduction:\nThe calculated value is $\\text{ARR} = 0.1$. To express this with $4$ significant figures, we must add trailing zeros after the decimal point.\n$$\n\\text{ARR} = 0.1000\n$$\nFor the relative risk reduction:\nThe calculated value is $\\text{RRR} = 0.4$. To express this with $4$ significant figures, we similarly add trailing zeros.\n$$\n\\text{RRR} = 0.4000\n$$\nThe final answer is required in a row matrix format $\\begin{pmatrix}\\text{ARR}  \\text{RRR}\\end{pmatrix}$.\nThe values are $\\text{ARR} = 0.1000$ and $\\text{RRR} = 0.4000$.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 0.1000  0.4000 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "Beyond managing individual patients, a key aspect of infectious disease practice is understanding population-level dynamics and prevention. This problem introduces the Population-Attributable Fraction (PAF), a powerful epidemiological tool to quantify the public health impact of a given risk factor, such as prior antibiotic use . You will derive the formula from first principles and apply it to estimate the burden of CDI attributable to a specific antibiotic, linking clinical observation to stewardship interventions.",
            "id": "4816270",
            "problem": "A hospital-based case-control study investigates risk factors for Clostridioides difficile infection (CDI) among adults on inpatient medical wards. After multivariable adjustment for relevant confounders, the association between prior clindamycin exposure and CDI yields an adjusted odds ratio (OR) of $3.0$. The prevalence of clindamycin exposure in the source population during the relevant risk window is $0.20$. Assume the following: (i) Clostridioides difficile infection (CDI) incidence is sufficiently low in the source population over the study interval that the odds ratio (OR) approximates the relative risk (RR), (ii) removal of exposure would reduce risk in the exposed to the risk observed in the unexposed without compensatory changes in other risks, and (iii) confounding has been adequately controlled so that the estimated association is causal. Starting from the fundamental definition of the population-attributable fraction (PAF) as the proportional reduction in population risk that would occur if the exposure were eliminated, derive an expression for PAF in terms of the exposure prevalence and the relative risk. Then, using the provided study parameters, compute the numerical value of the population-attributable fraction for clindamycin exposure. Express your final answer as a decimal (not a percentage) and round to four significant figures.",
            "solution": "The problem asks for two parts: first, to derive an expression for the population-attributable fraction (PAF) in terms of exposure prevalence and relative risk, and second, to compute its numerical value based on the provided study data.\n\nLet us define the following quantities:\n- $R_{pop}$: The overall risk (incidence) of the disease in the total population.\n- $R_{exp}$: The risk of the disease in the group exposed to the risk factor.\n- $R_{unexp}$: The risk of the disease in the group not exposed to the risk factor.\n- $P_e$: The prevalence of the exposure in the population.\n- $P_{ne}$: The prevalence of non-exposure in the population, where $P_{ne} = 1 - P_e$.\n- $RR$: The relative risk, defined as the ratio of the risk in the exposed to the risk in the unexposed, $RR = \\frac{R_{exp}}{R_{unexp}}$.\n\nThe population-attributable fraction (PAF) is defined as the proportional reduction in population risk that would occur if the exposure were eliminated. Mathematically, this is expressed as:\n$$\n\\text{PAF} = \\frac{R_{pop} - R'_{pop}}{R_{pop}}\n$$\nwhere $R'_{pop}$ is the new, counterfactual risk in the population after the complete removal of the exposure.\n\nThe overall risk in the population, $R_{pop}$, is a weighted average of the risks in the exposed and unexposed subgroups, weighted by their respective prevalences:\n$$\nR_{pop} = (R_{exp} \\times P_e) + (R_{unexp} \\times P_{ne})\n$$\nSubstituting $P_{ne} = 1 - P_e$, we have:\n$$\nR_{pop} = (R_{exp} \\times P_e) + (R_{unexp} \\times (1 - P_e))\n$$\nAccording to assumption (ii), if the exposure were eliminated, those individuals who were previously exposed would now experience the risk of the unexposed. Therefore, the entire population would have a risk equal to $R_{unexp}$. The new population risk, $R'_{pop}$, is thus:\n$$\nR'_{pop} = R_{unexp}\n$$\nSubstituting this into the definition of PAF:\n$$\n\\text{PAF} = \\frac{R_{pop} - R_{unexp}}{R_{pop}}\n$$\nNow, we substitute the expression for $R_{pop}$:\n$$\n\\text{PAF} = \\frac{[(R_{exp} \\times P_e) + (R_{unexp} \\times (1 - P_e))] - R_{unexp}}{(R_{exp} \\times P_e) + (R_{unexp} \\times (1 - P_e))}\n$$\nLet's simplify the numerator:\n$$\n\\text{Numerator} = R_{exp} P_e + R_{unexp} - R_{unexp} P_e - R_{unexp} = R_{exp} P_e - R_{unexp} P_e = P_e (R_{exp} - R_{unexp})\n$$\nSo the expression for PAF becomes:\n$$\n\\text{PAF} = \\frac{P_e (R_{exp} - R_{unexp})}{R_{pop}} = \\frac{P_e (R_{exp} - R_{unexp})}{(R_{exp} \\times P_e) + (R_{unexp} \\times (1 - P_e))}\n$$\nTo express this in terms of $RR$ and $P_e$, we can divide both the numerator and the denominator by $R_{unexp}$ (assuming $R_{unexp}  0$):\n$$\n\\text{PAF} = \\frac{P_e \\left(\\frac{R_{exp}}{R_{unexp}} - \\frac{R_{unexp}}{R_{unexp}}\\right)}{\\left(\\frac{R_{exp}}{R_{unexp}} \\times P_e\\right) + \\left(\\frac{R_{unexp}}{R_{unexp}} \\times (1 - P_e)\\right)}\n$$\nSubstituting $RR = \\frac{R_{exp}}{R_{unexp}}$ into this equation, we get:\n$$\n\\text{PAF} = \\frac{P_e (RR - 1)}{(RR \\times P_e) + (1 \\times (1 - P_e))}\n$$\nSimplifying the denominator:\n$$\n\\text{Denominator} = P_e \\cdot RR + 1 - P_e = 1 + P_e \\cdot RR - P_e = 1 + P_e(RR - 1)\n$$\nThus, the derived expression for PAF in terms of exposure prevalence ($P_e$) and relative risk ($RR$) is:\n$$\n\\text{PAF} = \\frac{P_e(RR - 1)}{1 + P_e(RR - 1)}\n$$\nThis completes the first part of the problem.\n\nFor the second part, we must compute the numerical value of the PAF. The problem provides the following parameters:\n- The prevalence of clindamycin exposure in the source population, $P_e = 0.20$.\n- The adjusted odds ratio (OR) is $3.0$.\n- Assumption (i) states that the odds ratio approximates the relative risk, so we can set $RR \\approx 3.0$.\n\nSubstituting these values into the derived formula for PAF:\n$$\n\\text{PAF} = \\frac{0.20(3.0 - 1)}{1 + 0.20(3.0 - 1)}\n$$\nFirst, calculate the term $(RR - 1)$:\n$$\n3.0 - 1 = 2.0\n$$\nNow, substitute this back into the equation:\n$$\n\\text{PAF} = \\frac{0.20(2.0)}{1 + 0.20(2.0)}\n$$\nCalculate the numerator and the term in the denominator:\n$$\n\\text{Numerator} = 0.20 \\times 2.0 = 0.40\n$$\n$$\n\\text{Denominator} = 1 + (0.20 \\times 2.0) = 1 + 0.40 = 1.40\n$$\nSo, the PAF is:\n$$\n\\text{PAF} = \\frac{0.40}{1.40} = \\frac{4}{14} = \\frac{2}{7}\n$$\nTo express this as a decimal rounded to four significant figures, we perform the division:\n$$\n\\text{PAF} = \\frac{2}{7} \\approx 0.28571428...\n$$\nRounding to four significant figures gives:\n$$\n\\text{PAF} \\approx 0.2857\n$$\nThis value indicates that approximately $28.57\\%$ of *Clostridioides difficile* infections in this inpatient population are attributable to clindamycin exposure, under the specified assumptions.",
            "answer": "$$\\boxed{0.2857}$$"
        }
    ]
}